View in EDS HTML Full Text PDF Full Text

CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.

Saved in:
Bibliographic Details
Title: CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.
Authors: Kida S; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Department of Hematology and Oncology, Osaka General Medical Center, Osaka, Japan., Suga M; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Yamaguchi Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Ikeda S; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Kogue Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Osaka, Japan., Kawamoto R; Department of Clinical Laboratory and Biomedical Sciences, University of Osaka Graduate School of Medicine, Osaka, Japan., Shibata K; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Tsutsumi K; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Murakami H; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Mizuta E; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Mizutani Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Hosen N; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; World Premier International Immunology Frontier Research Center, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Center for Infectious Disease Education and Research, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 02; Vol. 75 (3). Date of Electronic Publication: 2026 Mar 02.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41770279
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kida+S%22">Kida S</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Department of Hematology and Oncology, Osaka General Medical Center, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Suga+M%22">Suga M</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Yamaguchi+Y%22">Yamaguchi Y</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Ikeda+S%22">Ikeda S</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Kogue+Y%22">Kogue Y</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Kawamoto+R%22">Kawamoto R</searchLink>; Department of Clinical Laboratory and Biomedical Sciences, University of Osaka Graduate School of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Shibata+K%22">Shibata K</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Tsutsumi+K%22">Tsutsumi K</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Murakami+H%22">Murakami H</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Mizuta+E%22">Mizuta E</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Mizutani+Y%22">Mizutani Y</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Hosen+N%22">Hosen N</searchLink>; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; World Premier International Immunology Frontier Research Center, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Center for Infectious Disease Education and Research, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2026 Mar 02; Vol. 75 (3). <i>Date of Electronic Publication: </i>2026 Mar 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41770279
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-026-04342-x
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kida S
      – PersonEntity:
          Name:
            NameFull: Suga M
      – PersonEntity:
          Name:
            NameFull: Yamaguchi Y
      – PersonEntity:
          Name:
            NameFull: Ikeda S
      – PersonEntity:
          Name:
            NameFull: Kogue Y
      – PersonEntity:
          Name:
            NameFull: Kawamoto R
      – PersonEntity:
          Name:
            NameFull: Shibata K
      – PersonEntity:
          Name:
            NameFull: Tsutsumi K
      – PersonEntity:
          Name:
            NameFull: Murakami H
      – PersonEntity:
          Name:
            NameFull: Mizuta E
      – PersonEntity:
          Name:
            NameFull: Mizutani Y
      – PersonEntity:
          Name:
            NameFull: Hosen N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2026 Mar 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 75
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1